• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国卫生研究院文献>Evidence-based Complementary and Alternative Medicine : eCAM >Efficacy and Safety of Yokukansan in Treatment-Resistant Schizophrenia: A Randomized Multicenter Double-Blind Placebo-Controlled Trial
【2h】

Efficacy and Safety of Yokukansan in Treatment-Resistant Schizophrenia: A Randomized Multicenter Double-Blind Placebo-Controlled Trial

机译：玉kan散在抗精神分裂症中的疗效和安全性：一项随机多中心双盲安慰剂对照的试验

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objectives. We aimed at evaluating both the efficacy and safety of TJ-54 (Yokukansan) in patients with treatment-resistant schizophrenia. This randomized, multicenter, double-blind, placebo-controlled study was conducted. Methods. One hundred and twenty antipsychotic-treated inpatients were included. Patients were randomized to adjuvant treatment with TJ-54 or placebo. During a 4-week follow-up, psychopathology was assessed using the Positive and Negative Syndrome Scale (PANSS). Results. TJ-54 showed a tendency of being superior to placebo in reduction total, positive, and general PANSS scores in treatment-resistant schizophrenia, but the difference was not statistically significant in both per-protocol set (PPS) and intention-to-treat (ITT). However, in PPS analysis, compared to the placebo group, the TJ-54 group showed statistically significant improvements in the individual PANSS subscale scores for lack of spontaneity and flow of conversation (TJ-54: −0.23 ± 0.08; placebo: −0.03 ± 0.08, P < 0.018), tension (TJ-54: −0.42 ± 0.09; placebo: −0.18 ± 0.09, P < 0.045), and poor impulse control (TJ-54: −0.39 ± 0.10; placebo: −0.07 ± 0.10, P < 0.037). Conclusions. The results of the present study indicate that TJ-54 showed a tendency of being superior to placebo in reduction PANSS scores in treatment-resistant schizophrenia, but the difference was not statistically significant. However, compared to the placebo group, TJ-54 group showed statistically significant improvements in the individual PANSS subscale scores.
机译：目标。我们旨在评估TJ-54（Yokukansan）在患有难治性精神分裂症患者中的疗效和安全性。进行了这项随机，多中心，双盲，安慰剂对照的研究。方法。包括120名接受抗精神病药物治疗的住院患者。患者被随机分配接受TJ-54或安慰剂的辅助治疗。在4周的随访中，使用阳性和阴性综合征量表（PANSS）评估了精神病理学。结果。 TJ-54在抗药性精神分裂症的总减少，阳性和一般PANSS评分方面显示出优于安慰剂的趋势，但按方案集（PPS）和意向性治疗（PPS）的差异均无统计学意义（ ITT）。但是，在PPS分析中，与安慰剂组相比，TJ-54组由于缺乏自发性和交谈流畅性，在各个PANSS子量表得分上具有统计学上的显着改善（TJ-54：-0.23±0.08；安慰剂：-0.03± 0.08，P <0.018），张力（TJ-54：-0.42±0.09;安慰剂：-0.18±0.09，P <0.045），冲动控制差（TJ-54：-0.39±0.10;安慰剂：-0.07±0.10 ，P <0.037）。结论。本研究的结果表明，在抗药性精神分裂症中，TJ-54在降低PANSS评分方面表现出优于安慰剂的趋势，但差异无统计学意义。但是，与安慰剂组相比，TJ-54组在各个PANSS子量表得分上显示出统计学上的显着改善。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号